Author

J. T. Siveke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Assay:bulk RNA-seq· 5 Organism:mouse· 5 Research Focus:cancer & tumor microenvironment· 4 Organism:human· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2

Frequent Co-Authors

P. F. Cheung· 4 shared A. Scarpa· 3 shared C. Neander· 3 shared M. Trajkovic-Arsic· 3 shared R. T. Lawlor· 3 shared A. Tannapfel· 2 shared C. Vicentini· 2 shared D. Behrens· 2 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

P. F. Cheung

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Differential Activity of MAPK signalling Defines Fibroblast Subtypes in Pancreatic Cancer

L. Veghini, D. Pasini, P. Delfino, V. Corbo, E. Fiorini, F. Lupo, M. Bevere, C. Luchini, R. T. Lawlor, A. Scarpa, P. F.-Y. Cheung, J. T. Siveke, C. Vicentini, D. Filippini, S. L. D'Agosto, , R. Fang

This study identifies MAPK signalling as defining fibroblast subtypes in pancreatic cancer, linking MAPKhigh CAFs to poor prognosis and immune evasion.

bioRxiv · Oct 30, 2023Cancer Biology

Development of potent dual BET/HDAC inhibitors via pharmacophore merging and structure-guided optimization

N. Bauer, D.-I. Balourdas, J. R. Schneider, X. Zhang, L. M. Berger, B.-T. Berger, N. A. Klopp, J. T. Siveke, S. Knapp, A. C. Joerger

This study develops potent dual BET/HDAC inhibitors through pharmacophore merging and structure-guided optimization, showing improved potency and efficacy in cancer cell models.

bioRxiv · Jul 18, 2023 · PreprintBiochemistry

Co-inhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription

D. P. Cameron, J. Grosser, S. Ladigan, V. Kuzin, E. Iliopoulou, A. Wiegard, H. Benredjem, S. T. Liffers, S. Lueong, P. F. Cheung, D. Vangala, M. Pohl, R. Viebahn, C. Teschendorf, H. Wolters, , L. Baranello

The paper shows that combining TOP1 and BRD4 inhibitors selectively kills pancreatic cancer cells by inducing readthrough transcription, without harming normal cells.

bioRxiv · Feb 10, 2023Cancer Biology

SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis

A. J. Njouendou, A. A. Z. Tiofack, R. N. Kenfack, S. N. Ananga, E. H. M. D. Bell, G. Simo, J. D. Hoheisel, J. T. Siveke, S. S. Lueong

The paper identifies SOX2 amplification as a driver of tumor aggressiveness by sustaining inflammation through the FOSL2/IL6 axis, leading to DNA damage and genome instability.

bioRxiv · Jun 9, 2022 · PreprintCancer Biology

Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer

L. K. Godfrey, J. Forster, S.-T. Liffers, C. Schroeder, J. Koester, L. Henschel, K. U. Ludwig, M. Trajkovic-Arsic, D. Behrens, A. Scarpa, R. T. Lawlor, K. E. Witzke, B. Sitek, S. A. Johnsen, S. Rahmann, , J. T. Siveke

This study identifies adaptive DNA methylation changes and clonal expansion as mechanisms of resistance to MEKi in PDAC, showing reversibility upon drug withdrawal.

bioRxiv · May 20, 2022 · PreprintCancer Biology

Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma

I. Heid, S. Karakaya, C. Muench, S. S. Lueong, A. M. Winkelkotte, S. T. Liffers, L. Godfrey, P. F. Cheung, K. Savvatakis, G. J. Topping, F. Englert, L. Kritzner, M. Grashei, T. Kunzke, N. Sun, , J. T. Siveke

This study identifies functional metabolic differences between PDAC subtypes and shows that non-invasive HP-MRS can detect glycolytic tumor metabolism.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology

Progranulin promotes immune evasion of pancreatic adenocarcinoma through regulation of MHCI expression

P. F. Cheung, J. Yang, K. Krengel, K. Althoff, C. Yip, E. H. Siu, L. W. Ng, K. S. Lang, L. Cham, D. R. Engel, C. Soun, I. Cima, B. Scheffler, J. K. Striefler, M. Sinn, , J. T. Siveke

This study shows that tumor-derived progranulin (PGRN) promotes immune evasion in pancreatic ductal adenocarcinoma by reducing MHC class I expression, and blocking PGRN enhances immune response and slows tumor progression.

bioRxiv · Feb 24, 2021 · PreprintCancer Biology

MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages

P. Delfino, C. Neander, D. Filippini, S. D'Agosto, C. Vicentini, E. Fiorini, F. Lupo, C. Fiorini, B. Rusev, G. Temgue Tane, F. De Sanctis, M. Simbolo, S. Ugel, V. Bronte, M. Fassan, , V. Corbo

This study shows that MEK inhibition in mouse pancreatic cancer reduces anti-inflammatory macrophages and enhances gemcitabine efficacy by altering the tumor microenvironment.

bioRxiv · Sep 8, 2019 · PreprintCancer Biology

MYCN-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma

B. Tjaden, K. Baum, V. Marquardt, M. Simon, M. Trajkovic-Arsic, T. Kouril, B. Siebers, J. Lisec, J. T. Siveke, J. H. Schulte, U. Benary, M. Remke, J. Wolf, A. Schramm

This study shows that MYCN overexpression in neuroblastoma cells rewires metabolism, creating vulnerabilities that can be targeted with metabolic inhibitors.

bioRxiv · Sep 25, 2018Cancer Biology